

CorMedix Inc.  
Form 8-K  
February 22, 2016

---

---

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT  
Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934

Date of report (Date of earliest event reported): February 22, 2016

CORMEDIX INC.  
(Exact Name of Registrant as Specified in Charter)

|                                                                                             |                                              |                                                        |
|---------------------------------------------------------------------------------------------|----------------------------------------------|--------------------------------------------------------|
| Delaware<br>(State or Other<br>Jurisdiction<br>of Incorporation)                            | 001-34673<br><br>(Commission<br>File Number) | 20-5894890<br><br>(IRS Employer<br>Identification No.) |
| 1430 U.S. Highway 206, Suite 200, Bedminster NJ<br>(Address of Principal Executive Offices) |                                              | 07921<br>(Zip Code)                                    |

Registrant's Telephone Number, Including Area Code: (908) 517-9500

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
- 
-

Item 7.01. Regulation FD Disclosure.

On February 22, 2016, CorMedix Inc. issued a year end review of 2015, a copy of which is attached hereto as Exhibit 99.1.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

| Exhibit No. | Description                      |
|-------------|----------------------------------|
| <u>99.1</u> | Company Year End Review of 2015. |

---

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: February 22, 2016

CORMEDIX INC.

/s/ Randy Milby

Name: Randy Milby

Title: Chief Executive Officer